• Organization TypeInstitute
  • HeadquartersFrance

Carmat

CHRONIC HEART FAILURE IS A PROGRESSIVE DISEASE THAT AFFECTS MORE THAN 20 MILLION PEOPLE IN EUROPE AND THE UNITED STATES. HUNDREDS OF THOUSANDS OF THESE PATIENTS SUFFER FROM END-STAGE HEART FAILURE. Heat failure occurs when the pump function of someone’s heart is weakened. It primarily affects the left chamber of the heart, then the right chamber leading to biventricular failure. At this stage, vital organs such as the brain, liver and kidneys do not receive enough nutrients and oxygen to function properly. The main symptoms of the disease include fatigue, shortness of breath – (even at rest), and fluid retention. Carmat aims to provide a long-term solution to treat end-stage biventricular heart failure, rated as Class IV under the NYHA system, for which a heart transplant is still the only truly effective alternative treatment.
See more

Company Offices

  • France (headquarters)
  • Velizy-Villacoublay
  • 36, avenue de l'Europe Immeuble l'Etendar